SCHEMBL2664164

SCHEMBL2664164

N=CC(=O)Nc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 2/20 0.63
CYP1A2 P05177 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
MAOB P27338 4/20 0.57
MMP1 P03956 2/20 0.57
MMP2 P08253 2/20 0.57
MMP9 P14780 2/20 0.57
MAOA P21397 2/20 0.57
EGFR P00533 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
TP53 P04637 1/20 0.56
EPHX1 P07099 1/20 0.56
TSHR P16473 1/20 0.56
EPHX2 P34913 1/20 0.56
CDK9 P50750 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
NAPRT Q6XQN6 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302452 0.81 MMP1 (0.73) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL9840923 0.81 MMP1 (0.73) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL6302448 0.81 MMP1 (0.73) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL725250 0.79 TGM2 (0.65) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL2900749 0.79 TGM2 (0.65) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL5830369 0.77 TGM2 (0.63) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL9080645 0.77 TGM2 (0.63) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL6581501 0.77 TGM2 (0.63) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL81209 0.77 TGM2 (1.00) TGM2CYP1A2NPSR1MAOBMMP1
SCHEMBL6295972 0.77 MAOB (0.79) TGM2CYP1A2NPSR1MAOBMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0622358-A1 Phenylglycinamides of 4-imidazolylmethyl-phenyl-acetic acids and their use against hypertension and atherosclerosis BAYER AG (DE) 1994-11-02 EP claimed
US-11040939-B1 N-transfer reagent and method for preparing the same and its application NATIONAL CHENG KUNG UNIVERSITY (TW) 2021-06-22 US disclosed
US-10800922-B2 Pigment composition production method KAO CORPORATION (JP) 2020-10-13 US disclosed
WO-2017005711-A1 PHOSPHOROUS-AND SULFUR-SUBSTITUTED BENZODIAZEPINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-12 WO disclosed
US-8273777-B2 Glucokinase activators and methods of using same BRISTOL-MEYER SQUIBB COMPANY (US) 2012-09-25 US disclosed
US-20100324071-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2010-12-23 US disclosed
US-7812048-B2 Glucokinase activators and methods of using same BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-12 US disclosed
US-20090030046-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324071-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, HK1 TGM2 574/4885CYP1A2 3973/4885NPSR1 3043/4885
US-11040939-B1 N-transfer reagent and method for preparing the same and its application DNTT, NNMT, NMT1 TGM2 645/4885CYP1A2 547/4885NPSR1 1578/4885
US-20090030046-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, HK1 TGM2 574/4885CYP1A2 3973/4885NPSR1 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.